Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01038687 · ClinicalTrials.gov registry record · Phase 2
Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation
A Phase 2 study, sponsored by Michael Camilleri, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01038687: Completed Phase 2 study, sponsored by Michael Camilleri, MD.
NCT01038687 is a Phase 2 study that has completed, run by Michael Camilleri, MD. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01038687, a Phase 2 study, has completed, sponsored by Michael Camilleri, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a single-center, randomized, parallel group, double-blind, placebo-controlled, dose response, pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on gastric, intestinal and colonic transit in patients with functional constipation.
Interventions
- DRUG placebo
- DRUG A3309
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01038687
The ClinicalTrials.gov registry entry for NCT01038687 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael Camilleri, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01038687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01038687 about?
NCT01038687 is a clinical study titled "Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation". This is a single-center, randomized, parallel group, double-blind, placebo-controlled, dose response, pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on gastric, intestinal and colonic transit in patients with functional constipation.
What is the current status of trial NCT01038687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2010-01. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01038687?
The interventions under investigation include: placebo (DRUG), A3309 (DRUG).
Who is sponsoring clinical trial NCT01038687?
This trial is sponsored by Michael Camilleri, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.